HIV-1 reverse transcriptase and antiviral drug resistance. Part 2

Kalyan Das, Eddy Arnold

Research output: Contribution to journalReview articlepeer-review

77 Scopus citations


Structures of RT and its complexes combined with biochemical and clinical data help in illuminating the molecular mechanisms of different drug-resistance mutations. The NRTI drugs that are used in combinations have different primary mutation sites. RT mutations that confer resistance to one drug can be hypersensitive to another RT drug. Structure of an RT-DNA- nevirapine complex revealed how NNRTI binding forbids RT from forming a polymerase competent complex. Collective knowledge about various mechanisms of drug resistance by RT has broader implications for understanding and targeting drug resistance in general. In Part 1, we discussed the role of RT in developing HIV-1 drug resistance, structural and functional states of RT, and the nucleoside/ nucleotide analog (NRTI) and non-nucleoside (NNRTI) drugs used in treating HIV-1 infections. In this part, we discuss structural understanding of various mechanisms by which RT confers antiviral drug resistance.

Original languageEnglish (US)
Pages (from-to)119-128
Number of pages10
JournalCurrent Opinion in Virology
Issue number2
StatePublished - Apr 2013

All Science Journal Classification (ASJC) codes

  • Virology


Dive into the research topics of 'HIV-1 reverse transcriptase and antiviral drug resistance. Part 2'. Together they form a unique fingerprint.

Cite this